Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS

395 patients (D-VRd 197, VRd 198), median follow-up 58.7 months. Overall MRD-negativity 10^-5: 60.9% vs 39.4% (OR 2.37, 95% CI 1.58-3.55, P<.0001); 10^-6: 46.2% vs 27.3% (OR 2.24, 95% CI 1.48-3.40, P=0.0001). Sustained MRD negativity ≥12 months 10^-5: 49.2% vs 27.3%; 10^-6: 34.0% vs 16.2% (each P<.0001), with similar benefits at ≥24 and ≥36 months. Among patients who achieved MRD negativity, PFS trended in favor of D-VRd (10^-5 HR 0.61, 95% CI 0.35-1.06, P=0.0755).

Blood AdvPubMed 42234958